Rivus Pharmaceuticals is pioneering a new class of investigational medicines known as Controlled Metabolic Accelerators (CMAs), which are designed to enhance cardiometabolic health. These oral small molecules work by leveraging the natural process of mitochondrial uncoupling, which plays a significant role in energy expenditure and fat metabolism. By activating this process, CMAs aim to facilitate fat-specific weight loss while preserving muscle mass, thereby addressing obesity and its associated cardiometabolic diseases. The lead candidate, HU6, is currently in development for various conditions, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD), and Type 2 diabetes.

Rivus employs a sophisticated discovery platform that integrates an artificial intelligence and machine learning (AI/ML) classifier model, trained on proprietary datasets, to identify and develop additional CMA candidates. This innovative approach not only enhances the efficiency of drug discovery but also targets therapeutic areas with significant unmet medical needs. The clinical potential of CMAs is underscored by promising results from Phase 2 trials, which have shown improvements in key disease markers such as blood pressure, inflammation, and glycemic control, all while maintaining lean muscle mass and reducing the risk of weight regain.

United States

Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF).

Rivus Pharmaceuticals

Company Details